Claims

1. Use of fibrinogen multimers having at least 6 fibrinogen units as an ingredient of a fibrin sealant.

2. Use according to claim 1 having 6 - 15 fibrinogen units as an ingredient of a fibrin sealant.

3. Use according to claim 1 wherein the fibrinogen multimers have 6 to 9 fibrinogen units.

4. Use according to ~~any of claims 1 to 3~~ wherein the amount of fibrinogen multimers having 6 to 9 fibrinogen units is at least 5% (w/w) of total fibrinogen.

5. A method for the production of a fibrin sealant comprising fibrinogen multimers having at least 6 fibrinogen units comprising the steps of

   - resuspending cryoprecipitate
   - adding sucrose to yield a concentration of 60 to 70% (w/w),
   - adding glycine to yield a concentration of 0.1 to 0.3 M,
   - heating to 60°C for 15 - 20 hours,
   - removing the glycine and the sucrose by dialysis,
   - adding a protease inhibitor.

6. The method of claim 5, wherein the dialysis is conducted against a buffer comprising NaCl, glycine and $CaCl_2$.

7. The method of claim 5, wherein the protease inhibitor is tranexamic acid in a concentration of 8 - 12% (w/w) and/or arginine in a concentration of 1 - 3% (w/w).

8. A fibrin sealant comprising multimeric fibrinogen of at least 6 fibrinogen units.